Mimrylo (rusfertide) for Polycythemia vera
What the FDA decided
The FDA approved Takeda / Protagonist Therapeutics's NDA for Mimrylo (rusfertide) in Polycythemia vera. First hepcidin mimetic approved for polycythemia vera.
Who this decision matters to
Polycythemia Vera is a myeloproliferative neoplasm in which bone marrow produces too many red blood cells, leading to thick blood that carries oxygen less effectively and increases clot risk. Most patients have a mutation in the JAK2 gene. While some people with PV have no symptoms, others experience fatigue, headaches, vision problems, and risk of blood clots and bleeding.
Prevalence: Approximately 44-57 cases per million people; median age of diagnosis is 65 years. See our full Polycythemia Vera page for current treatments, recruiting trials, and community resources.
Where Polycythemia Vera treatment stands today
Research in Polycythemia Vera is expanding beyond traditional phlebotomy and aspirin toward targeted molecular therapies that address the underlying JAK2 mutations driving the disease. JAK2 inhibitors, HDAC inhibitors, and other innovative agents are being tested to reduce clot risk, lower disease burden, and improve quality of life for patients living with this condition. Ongoing trials are examining how best to combine these therapies and how to use genetic and molecular testing to predict which patients need more intensive treatment. While phlebotomy and low-dose aspirin remain important foundational treatments, newer agents provide additional options, particularly for high-risk patients. In August 2026 the FDA approved rusfertide (Mimrylo), a once-weekly injection under the skin that mimics hepcidin, the body's iron-regulating hormone, to treat erythrocytosis in adults with polycythemia vera. In its Phase 3 VERIFY trial, where it was added to usual care, 76.9% of patients no longer qualified for a phlebotomy during weeks 20 to 32, against 32.9% on placebo. Discussing trial opportunities with your hematologist allows you to participate actively in decisions about treatment intensity and approach.
Meanwhile, 61 Polycythemia Vera trials are recruiting
Whatever the FDA decides here, research on Polycythemia Vera does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Polycythemia Vera
Get notified when new polycythemia-vera trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Mimrylo?
The FDA has already decided: the application was approved. See the outcome details above.
What is Mimrylo being reviewed for?
Takeda / Protagonist Therapeutics submitted a NDA for Mimrylo in Polycythemia vera. First hepcidin mimetic approved for polycythemia vera.
What happens after the Mimrylo decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Takeda press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.